TY  - JOUR

T1  - PCN259 SHOULD HEALTH STATE UTILITY VALUES (HSUVS) IN CANCER IMMUNOTHERAPIES (IOS) BE ANALYZED BY TIME TO DEATH (TTD) OR PROGRESSION STATUS? RESULTS OF A SIMULATION STUDY

JO  - Value in Health

PY  - 2019/05/01

AU  - Hatswell AJ

AU  - Bullement A

AU  - Schlichting M

AU  - Bharmal M

ED  - 

DO  - DOI: 10.1016/j.jval.2019.04.380

PB  - Elsevier BV

VL  - 22

SP  - S105

EP  - S105

Y2  - 2024/12/26

ER  -